Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly
Zuellig Pharma announced on 12 March 2026 the acquisition of all rights, title, and interest...
Deals
Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration
Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with...
Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy – RMB 240M Investment Advances CD44/CD133 Autologous Treatment for Recurrent Glioblastoma
Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the...
Mannerchem Secures Exclusive China Rights to Kintor’s AI-Discovered Whitening Ingredient Oximidol KT-939
Mannerchem, the China-based specialty chemicals company, has formed a strategic partnership with domestic biopharmaceutical firm...
GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors
GlycoNex, Inc. announced on March 23, 2026, a strategic collaboration agreement with Nippon Kayaku Co.,...
Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M
Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement...
Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration
Menarini Group, the Italian pharmaceutical company, and the Shanghai Angel Baby Charity Foundation have officially...
IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers
IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and...
Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value
Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its...
Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) has entered into a strategic exclusive licensing agreement...
Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio
Merck KGaA (ETR: MRK) has officially closed its acquisition of the chromatography business from JSR...
Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC
Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a...
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical...
Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology
Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic...
Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio
Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) is in advanced negotiations to acquire Organon & Co....
Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
Oricell Therapeutics Co., Ltd. announced completion of a US$110 million+ pre‑IPO financing round, positioning the cell...
Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced that partner Gilead Sciences Inc. (NASDAQ: GILD) has exercised its exclusive...
Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline
Sinocelltech Group Ltd (SHA: 688520) announced plans to raise up to RMB 900 million (US$132 million) through a...
NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform
NorrDia Medical, a Ningbo‑based blood purification specialist, announced completion of a RMB 100 million+ (US$14.6 million) financing...
Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners
Vivatides Therapeutics announced the completion of an oversubscribed USD 54 million Series A financing round,...